Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today reported results for the third quarter ended September 30, 2004. During the third full quarter since launch, Cubist achieved $18.0 million in revenue for its flagship antibiotic product Cubicin(R) (daptomycin for injection), an increase of 35%, or $4.7 million, from second quarter 2004 CUBICIN revenue.
